Enyo Pharma

Developing therapeutics for diseases with impaired kidney function

Lyon, France · Founded 2014 · $117.5M raised

Headquarters
Lyon
Employees
11–50
Founded
2014
Business Model
B2B
Total Funding
$117.5M
Last Round
$7.0M Extension RoundJun 2025
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 4 investors for this company. The full record is or through the API.

About

ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in chronic kidney disease and rare kidney diseases such as Alport syndrome. Vonafexor (EYP001) is a synthetic, non-steroidal farnesoid X receptor agonist administered as a once-daily oral tablet and mainly distributed to the kidney and the liver. Clinical development is supported by 11 completed studies, including seven Phase 1 and four Phase 2a trials. ENYO began in 2014 when experts in virus-host protein interactions from the French Infectiology Research Center (Inserm) in Lyon and pharmaceutical executives built a drug discovery platform based on virus-inspired biomimetism.

Summary

Enyo Pharma is a Biotech company based in Lyon, France, founded in 2014. It has raised $117.5M in total across 4 rounds, most recently a $7.0M Extension Round in Jun 2025. Investors include Vesalius Biocapital IV, OrbiMed and Andera Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundSeries C ExtensionJun 2025
$7.0M

Sign up to see all 4 events

Funding: Series A through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Enyo Pharma on Indexed.vc
<a href="https://indexed.vc/companies/enyo-pharma"><img src="https://indexed.vc/api/badge/company/enyo-pharma" alt="Enyo Pharma on Indexed.vc" width="260" height="76" /></a>